AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04885309 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Stimulator-guided Obturator Nerve Block
Description: Following the confirmation of spinal anesthesia level in the patients in the ONB group while in the lithotomy position, ONB was applied unilaterally or bilaterally, depending on the tumor position. A needle with a nerve stimulator was advanced vertically 2 cm below and 2 cm from the pubic tubercle. The needle is inserted through the skin and into the lower ramus of the pubic bone. When contraction was observed in the adductor muscle groups and the aspiration was negative, 10 mL 0.25% levobupivacaine at 0.3-0.5 mA was administered. The operation was started 10 minutes after the injection. TURBT operations were performed with a 30 degree optic and a 26 F bipolar resectoscope. All spinal anesthesia and ONB procedures were performed by the same anesthesia team. All TURBT operations were performed by the same surgeon.
Study NCT04885309 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Nerve Stimulator-guided Obturator Nerve Block
Description: Following the confirmation of spinal anesthesia level in the patients in the ONB group while in the lithotomy position, ONB was applied unilaterally or bilaterally, depending on the tumor position. A needle with a nerve stimulator was advanced vertically 2 cm below and 2 cm from the pubic tubercle. The needle is inserted through the skin and into the lower ramus of the pubic bone. When contraction was observed in the adductor muscle groups and the aspiration was negative, 10 mL 0.25% levobupivacaine at 0.3-0.5 mA was administered. The operation was started 10 minutes after the injection. TURBT operations were performed with a 30 degree optic and a 26 F bipolar resectoscope. All spinal anesthesia and ONB procedures were performed by the same anesthesia team. All TURBT operations were performed by the same surgeon.
Study NCT01521507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Warm Compress Therapy + Lid Scrub
Description: At-home daily warm compress therapy and lid hygiene
Study NCT02153866 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rotavirus vaccine
Description: 3ml/dose, oral
Study NCT02153866 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rotavirus vaccine
Description: 3ml/dose, oral
Study NCT02153866 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: measles-rubella vaccine
Description: 0.5ml per dose, subcutaneous injection
Study NCT02153866 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: measles-rubella vaccine
Description: 0.5ml per dose, subcutaneous injection
Study NCT02153866 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: measles-mumps-rubella vaccine
Description: 0.5ml per dose, subcutaneous injection
Study NCT02153866 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: measles-mumps-rubella vaccine
Description: 0.5ml per dose, subcutaneous injection
Study NCT03739710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administered.
Study NCT03739710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered.
Study NCT03739710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feladilimab
Description: Feladilimab will be administered.
Study NCT03739710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered.
Study NCT03739710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4428859A
Description: GSK4428859A/EOS884448 will be administered.
Study NCT03739710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.
Study NCT03739710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK6097608
Description: GSK6097608 will be administered.
Study NCT02316704 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA with G7 PPS coted acetabular component
Study NCT01969006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine ½%
Study NCT01969006 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Needle prick
Study NCT02545608 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Restylane Vital
Study NCT02545608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Vital
Study NCT03694717 — intervention group
Intervention type: DRUG
Intervention: Saline Solution for Injection
Description: The fluid expansion will consist in a less than 10 min infusion of 500 milliliters of saline through a central venous catheter (jugular). The duration of infusion will be controlled by an airbag pressurized at 300 mmHg.
Study NCT03275740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06755347 intravenous healthy participant
Description: Single doses of PF-06755347 will be administered intravenously dose levels 1, 2, 3, 4, 5, and 6.
Study NCT03275740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intravenous healthy participant
Description: Placebo comparator
Study NCT03275740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06755347 subcutaneous healthy participant
Description: single doses of PF-06755347 will be administered subcutaneously at dose levels of SC1, SC2, SC3, SC4, and SC5.
Study NCT02316704 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA with G7 OsseoTi coted acetabular component
Study NCT03275740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo subcutaneous healthy participant
Description: placebo comparator
Study NCT03275740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06755347 subcutaneous ITP
Description: single doses of PF-06755347 will be administered subcutaneously at 2 dose levels tested in healthy participants
Study NCT02731495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EGCG
Description: EGCG (Epigallocatechin -3-gallate)
Study NCT02731495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (deionized water)
Study NCT01290614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist based QI program
Description: Per a study protocol, the pharmacist will call each subject (who has not opted out) and discuss their CKD. In brief, the pharmacist will introduce themselves, ask the subject if they have time to discuss their medical care, inform the subject that they have CKD, briefly discuss CKD, ask the subject if they can come for labs, discuss hypertension management as appropriate, and answer any questions. In addition, for subjects with poorly controlled hypertension, the study pharmacist will arrange for a nutrition consult for a low sodium diet, a mainstay of hypertension management in patients with CKD. Finally, for patients with advanced CKD (GFR \<30 mL/min per 1.73 m2) who are not seeing a nephrologist, the study pharmacist will arrange for a nephrology outpatient appointment to assess the need for placement of access for renal replacement therapy.
Study NCT01290614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients in the control arm will continue to receive usual care from their VA providers.
Study NCT01358825 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sampling
Description: A blood sample will be taken at 5 years of age, after vaccination in the primary study.
Study NCT01153737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT)
Description: Ten treatment sessions of 30 minutes of MT or TENS on alternate days were provided by primary care physical therapists. MT techniques: neuromuscular technique, postisometric stretching, spray and stretching and Jones technique.
Study NCT01153737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Ten treatment sessions of 30 minutes of MT or TENS on alternate days were provided by primary care physical therapists. TENS electrode placement were: in the painful area, in the metamere or in the nerve´s pathway. It was applied at a frequency of 80 Hz, with ≤150 µs pulse duration and adjusted amplitude.
Study NCT00509470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan plus hydrochlorothiazide
Description: Combination therapy with telmisartan (40 mg/day) plus hydrochlorothiazide (12.5 mg/day): If blood pressure is not reach to lower than 140/90 mmHg, dose of telmisartan can be increased to 80 mg/day
Study NCT00509470 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Study NCT03104179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosorb Adsorber
Description: Cytokine adsorption during CPB
Study NCT03641040 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Video-oculography
Description: measure and analyze angles of ocular deviations between dominant and non-dominant eye using VOG with alternate cover.
Study NCT03641040 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Alternative prism cover test
Description: measure and analyze angles of ocular deviations between dominant and non-dominant eye using APCT
Study NCT04079595 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Head immobilization mask
Description: Immobilization
Study NCT04079595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Head immobilization mask
Description: Immobilization
Study NCT02564458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval Exercise Training/Motivational Accelerometry
Description: During the 5-12 weeks before allogeneic stem cell transplant, the patient will participate in an at home, interval exercise training (IET) program, as well as wear a physical activity tracker, the FitBit Surge, combined with a weekly motivational call, termed Motivational Accelerometry (MA). The combined intervention is referred to as (IET/MA). The first week of the IET program consists of the participants being asked to engage in 30 minutes of aerobic exercise at any intensity for 3-4 days. For weeks two and beyond, patients be asked to undergo 3-4 sessions of IET, consisting of a 5 minute warm-up and five 2-minute intervals, with the goal of reaching 80% MHR, separated by 3 minutes of recovery/light activity in between each interval. Each exercise session is a total of 30 minutes. In addition, each week prior to transplant, the patient will receive a weekly check-in/motivational call from the study staff in order to track progress and motivate the patient to continue participation.
Study NCT05441631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: * Preparation: 50 IU of rapidly acting insulin in 50 ml of 0.9% saline solution was delivered through a 50-ml syringe-driven pump.~* Monitoring: The insulin dose was adjusted to whole-blood glucose levels using glucometer every hour and insulin infusion was continued till BG level (Targeted level) was 80-110 mg, and then BG levels were estimated four-hourly~* Insulin dose was titrated according to the Leuven titration protocol (15)
Study NCT05441631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Insulin
Description: * Insulin dose was titrated according to the Blood glucose level~* monitoring according to glucose in urine
Study NCT01814475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A: Fludarabine + Busulphan
Description: Fludarabine 30 mg/m2/d, day -8 to day-3 and Busulphan (Busilvex) 0,8 mg/Kg/i.v. dose x 4 doses on days -5,-4 and x 2 doses on day -3, total dose 8 mg/Kg) prior allogenic transplant (day zero)
Study NCT01814475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: Fludarabine + Thiotepa
Description: Fludarabine 30 mg/m2/d day -8 to day -3 Thiotepa 6 mg/Kg for 2 doses ( days -4, -3) prior allogeneic transplant (day zero)
Study NCT01463241 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral and Affective Skills in Coping (BASIC)
Description: The investigator's seek to develop a treatment protocol that integrates five core intervention principles that are common to evidence-based treatments for youth depression, anxiety, and disruptive behavior problems. The protocol will be designed for implementation in everyday community practice settings by practitioners. The BASIC protocol will include (a) a therapist manual guiding the use of five BASIC skills \[Belief Repair, Action, Solving Problems, Incentives, and Calming\]; (b) child and parent materials to facilitate learning skills, practicing them in-session, and using them outside sessions; and (c) a decision tree to guide judgments about which skills to use and when to switch skills or treatment focus.
Study NCT04317040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efprezimod alfa
Description: Efprezimod alfa is given on Day 1.
Study NCT04317040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is given on Day 1.
Study NCT03266133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Education for Pregnancy
Description: Sleep education specific to pregnancy
Study NCT00004092 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or subcutaneously
Study NCT00004092 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Given IV or subcutaneously
Study NCT00004092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV
Study NCT00004092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00004092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV
Study NCT00004092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00004092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00004092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thiotepa
Description: Given IV
Study NCT00004092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Patients receive autologous peripheral blood stem cells
Study NCT00004092 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation
Description: Patients receive autologous peripheral blood stem cells
Study NCT03500640 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DPP Intensive: 30-minute calls
Description: Ongoing DPP intervention and behavioral progress review to prevent relapse and improve cardiometabolic and functional health targets as keys to healthy aging.
Study NCT03500640 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: DPP Support: 15-minute calls
Description: No further behavioral intervention materials provided; phone-contacts for mutual social support and accountability
Study NCT04676295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face and web-based lifestyle intervention
Description: Families are provided at baseline with one 60 min face-to-face dietary counseling session with nutritionist using family-oriented motivational interviewing and solution focusing techniques. The intervention continues in an interactive web-based portal where different modules include assignments, activities, and tests and related videos targeting five cardiovascular health-linked behaviors: 1) improving quality of fat in the diet, 2) increasing the consumption of foods rich in fiber, 3) decreasing the use of salt, 4) increasing physical activity and 5) reducing smoking.
Study NCT01961271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Please see Arm Description.
Study NCT01951560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: By infusion over 1 hour
Study NCT01951560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline solution
Description: By infusion over 1 hour
Study NCT00056979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAMPATH-1H
Study NCT00056979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD45
Study NCT00056979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506
Study NCT00056979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study NCT02186574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil
Study NCT02186574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study NCT03084692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Yoga and Resistance Exercise
Description: Combined Program of Yoga and Resistance Exercise
Study NCT03259087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3866
Description: Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) on Day 1 of each treatment period.
Study NCT03433482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY liquid
Description: At visit 1 (day 1), each subject will receive a single dose of the investigational MenACWY liquid vaccine (GSK3536820A) aged for approximately 24 months in Phase 1 of the study (subjects randomized to study arm ACWY_Liq24) or vaccine aged for 30 months in Phase 2 of the study (subjects randomized to study arm ACWY_Liq30), administered by intramuscular injection in the deltoid of the non-dominant arm.
Study NCT03433482 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY
Description: At visit 1 (day 1), each subject will receive a single dose of the MenACWY vaccine in the Phase1 of the study (subjects randomized to study arm ACWY_1) or in phase 2 of the study (subjects randomized to study arm ACWY_2), administered by intramuscular injection in the deltoid of the non-dominant arm.
Study NCT02518971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: 0.4 mg daily
Study NCT01313429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
Study NCT01313429 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic tumor Cell Vaccine (K562)
Description: 4 vaccines consisting of approximately 2.5E7 cells each will be delivered IM every 4 weeks for 6 months. If immune response is detected after first 6 vaccinations, 2 more may be given at 3 month intervals.
Study NCT01313429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each vaccine cycle.
Study NCT02448875 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CyPass Micro-Stent
Description: Small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye in order to reduce intraocular pressure. Designed to be permanently implanted in the eye.
Study NCT02448875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyPass Micro-Stent
Description: Small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye in order to reduce intraocular pressure. Designed to be permanently implanted in the eye.
Study NCT02448875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viscoelastic
Description: Healon 5 ophthalmic viscoelastic used to increase the size of the aqueous drainage area created by the CyPass Micro-Stent
Study NCT04100902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ODACTRA 12 SQ-HDM Sublingual Tablet
Description: Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
Study NCT04100902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sublingual tablet
Description: Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
Study NCT04145531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM JZP-458
Description: IM JZP-458 will be administered in Part A, Cohorts 1 \& 2
Study NCT04145531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV JZP-458
Description: IV JZP-458 will be administered in Part B
Study NCT04128059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVRS-GamVac-Combi
Description: BVRS-GamVac-Combi, a combined vector vaccine for the prevention of Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration
Study NCT04128059 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03487159 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRE (Magnetic Resonance Elastography)
Description: The device is using to evaluate liver fibrosis stage
Study NCT00314847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extra-Corporeal Life Support -Impella 2.5
Description: Percutaneous implantation of Impella pump for a duration of 3 days as a minimum and up to 7 days (recommended)
Study NCT02518971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one capsule daily
Study NCT02434770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 1
Description: Each dose of bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10\^6 cell culture infectious dose 50% (CCID50)/dose and 10\^5.8 CCID50/dose, respectively.